- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01153633
Trial on the Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel
Pilot, Randomised, Double-blind, Controlled Clinical Trial on the Combined Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel in the Reduction in Size and Change in Bioburden of Hard-to-heal Venous Leg Ulcers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
SUMMARY
Sponsor: B. BRAUN Medical AG
Trade name: Prontosan® Wound Irrigation Solution Prontosan® Wound Gel
Active substance: Polihexanide (0.1%) Betaine (0.1%)
Study Duration (per patient):
13 weeks, including the 1 week run in period
Primary Objective:
To evaluate the efficacy of the combination of Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel in the reduction of wound size of hard-to-heal venous leg ulcers compared to control saline irrigation solution and inactive gel.
Secondary Objectives:
To assess the change in bio-burden (assessment of organisms present) and to determine local tolerance as well as reduction in pain and to monitor exudate control.
Methodology:
A pilot randomised, double-blind, controlled clinical trial at a single centre
Planned number of patients:
A sample size of N= 15 evaluable patients was estimated for each treatment group (group "A" and "B"). Adding a dropout rate of approx. 25% results in a total number of patients for both treatment groups of N=38.
Study Visits:
Visit 0 (-1 week) - Screening Visit 1 ( Week 0) - Treatment and assessment visit Visit 2 (Week 1, day 7 +/- 1 day) - Treatment and assessment visit Visit 3 (Week 2, day14 +/- 1 day) - Treatment and assessment visit Visit 4 (Week 4, day 28 +/- 2 days) - Treatment and assessment visit Visit 5 (Week 8, day 56 +/- 2 days) - Treatment and assessment visit Visit 6 (Week 12, day 84 +/- 2 days) - End of study following 12 weeks of treatment or at healing whichever is soonest
The number of additional visits will be recorded in the Case Report Forms.
Treatment efficacy assessment:
Clinical signs and symptoms will be compared between the two randomised groups with microbiological analysis and, computer planimetry assessments of ulcer size, using Visitrak™ (Smith & Nephew), and digital photography at entry to the study, at each planned study visit and at healing or 12 weeks, whichever is soonest.
Tolerance assessment:
The tolerability of study treatment will be evaluation based on the intensity and the course of adverse events (undesired concomitant effects, both subjectively perceived symptoms and objectively detected signs of disease). Tolerance assessments will take place from visit 2 onwards
Assessment methods:
Assessment of clinical signs and symptoms, in particular related to development of infection:
- reduction of slough and necrotic tissue
- control of exudate
- presence of granulation tissue
- reduction of inflammatory signs (surrounding skin)
- pain
- Ulcer computerised planimetry using Visitrak™
- Microbiological analysis for bioburden (the bioburden within an ulcer relates to a microbiological qualitative and quantitative assessment of organisms present) assessed by wound swab or biopsy
- Serial photography with blinded assessment of progress using linear analogue scale
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Wales
-
Cardiff, Wales, United Kingdom, CF14 4XN
- Cardiff University, Department of Wound Healing
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females aged > 18 who are able to give informed consent
- Patients with a chronic venous leg ulcer at any location below the knee joint (CVI grade C6 according to CEAP classification = trophic lesions and open ulcer)
- Venous leg ulcer present for ≥4 weeks
- Surface area of the target ulcer ≥2cm2 and <100cm2 with the largest length not being >10cm
- ABPI ≥ 0.7
Exclusion Criteria:
- Age below 18 years
- Females of child bearing potential who are not willing to use a method of highly effective contraception during the entire study
- Pregnant or breast feeding women
- Signs and symptoms of clinical infection, or current use of antiseptics or antibiotics
- Involvement in other trials within the past 1 month
- Sensitivity to any of the components of Prontosan® or dressing material
- Intolerance to compression therapy
- Active osteomyelitis in the ulceration area
- Active rheumatoid or collagen disease of blood vessels treated with corticosteroids
- Chronic diseases that could impact the course of the study (malicious cancer, TB, AIDS, mental illnesses)
- Plasma protein below 4 g/dl
- Anaemia: haemoglobin below 10 g/dl
- Poorly controlled Diabetes (HBA1C > 12%)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prontosan Wound Solution and Gel
Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel.
Secondary dressing to be a semi occlusive dressing.
Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
|
The treatment procedures (after a 1 week run-in) include:
|
Placebo Comparator: Normal Saline and Placebo Gel
Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel.
Secondary dressing to be a semi occlusive dressing.
Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
|
The treatment procedures (after a 1 week run-in) include:
Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change of Wound Size From Baseline to Last Visit
Time Frame: 12 Weeks
|
12 Weeks
|
|
Healing of Target Ulcer atV6/EOS
Time Frame: 12 weeks
|
Number of ulcers healed at V6/EOS
|
12 weeks
|
Absolute Change of Target Ulcer From Baseline to Last Visit
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Different Microganisms at V6/EoS
Time Frame: 12 Weeks
|
12 Weeks
|
|
Pain
Time Frame: 12 Weeks
|
Absolute change (mm VAS) from baseline to V6/EoS.
Pain intensity assessed by patient.
At each study visit the patients assessed their pain intensity using a 100 mm Visual Analogue Scale (VAS).
Thereby 0 mm represented 'no pain' and 100 mm 'worst possible pain'.
|
12 Weeks
|
Condition of Wound Bed
Time Frame: 12 Weeks
|
Sum of granulation and epithelium (% of wound bed), absolute change from baseline to V6/EoS
|
12 Weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Keith Harding, MD, Cardiff University, Department of Wound Healing
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPM-G-H 0901
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcer
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Ortec InternationalCompletedVenous Leg Ulcer | Venous Stasis UlcerUnited States
-
Firstkind LtdTerminatedLeg Ulcer | Venous Leg Ulcer | Venous UlcerCanada
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States, Australia, Germany, Italy, United Kingdom, New Zealand, Ireland
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
Clinical Trials on Prontosan Wound Irrigation Solution and Prontosan Wound Gel
-
B. Braun Medical Inc.TerminatedWound of Lower Leg (Physical Finding)United States
-
The First Hospital of Jilin UniversityFujian Medical University Union Hospital; Shenzhen Second People's HospitalRecruitingBurns | Diabetic Foot Ulcer | Chronic Wound | Pressure Injury | Irrigation SolutionChina
-
Associazione Infermieristica per lo studio delle...B. Braun Medical SACompletedPressure Ulcer | Wound Cleansing | Chronic Wound CareItaly
-
Georgetown UniversityCompletedWound InfectionUnited States
-
Calvary Hospital, Bronx, NYB. Braun Medical SACompletedWound Care | Venous Ulcer Care | Wound Cleansing | Chronic Wound CareUnited States
-
University of Nevada, Las VegasRecruitingColorectal Disorders | Surgical Site Infection | Wound SurgicalUnited States
-
Wake Forest University Health SciencesRecruitingSpinal Cord Injuries | Pressure InjuriesUnited States
-
B. Braun Ltd. Centre of Excellence Infection ControlCompleted
-
SoftOx Solutions ASUnknown
-
Rochal Industries LLCThe University of Texas Health Science Center at San Antonio; Brooke Army Medical... and other collaboratorsNot yet recruiting